Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02456701
Title Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Kolltan Pharmaceuticals, Inc.

thyroid gland follicular carcinoma


CDX-3379 + Vemurafenib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST